Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRB2 | P62993 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL15789326 | 0.96 | TSHR (0.40) | TSHRMEN1KMT2AHTTHIF1A | |
| SCHEMBL28828027 | 0.96 | TSHR (0.40) | TSHRMEN1KMT2AHTTHIF1A | |
| SCHEMBL5164334 | 0.88 | ESR1 (0.42) | TSHRPOLBADRB2ADRB1ADRB3 | |
| SCHEMBL29111489 | 0.87 | TSHR (0.40) | TSHRMEN1KMT2AHTTHIF1A | |
| SCHEMBL11516982 | 0.85 | AR (0.47) | TSHRMEN1KMT2AHTTHIF1A | |
| SCHEMBL3860371 | 0.85 | TSHR (0.40) | TSHRMEN1KMT2AHTTPOLB | |
| SCHEMBL15789323 | 0.85 | AR (0.43) | TSHRMEN1KMT2AHTTHIF1A | |
| SCHEMBL11143170 | 0.84 | ADRB2 (0.38) | TSHRMEN1KMT2APOLBADRB2 | |
| SCHEMBL10867141 | 0.82 | TSHR (0.47) | TSHRPOLBADRB2ADRB1ADRB3 | |
| SCHEMBL15349 | 0.82 | HTT (0.53) | TSHRMEN1KMT2AHTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514791-B2 | Aesthetic dental filling material having high curing depth | IVOCLAR VIVADENT AG (LI) | 2026-01-06 | — | — | US | claimed |
| US-20250352435-A1 | AESTHETIC DENTAL FILLING MATERIAL HAVING HIGH CURING DEPTH | IVOCLAR VIVADENT AG (LI) | 2025-11-20 | — | — | US | claimed |
| US-12296031-B2 | Esthetic dental filling material with high depth of cure | IVOCLAR VIVADENT AG (LI) | 2025-05-13 | — | — | US | claimed |
| CN-113288817-B | Dental materials based on cyclizable polymeric crosslinkers | 义获嘉伟瓦登特公司 | 2024-06-14 | — | — | CN | claimed |
| US-11793732-B2 | Dental materials based on cyclopolymerizable crosslinkers | IVOCLAR VIVADENT AG (LI) | 2023-10-24 | — | — | US | claimed |
| US-20230059534-A1 | AESTHETIC DENTAL FILLING MATERIAL HAVING HIGH CURING DEPTH | IVOCLAR VIVADENT AG (LI) | 2023-02-23 | — | — | US | claimed |
| US-20230052305-A1 | Esthetic Dental Filling Material With High Depth Of Cure | IVOCLAR VIVADENT AG (LI) | 2023-02-16 | — | — | US | claimed |
| EP-4124331-A1 | AESTHETIC DENTAL FILLING MATERIAL WITH HIGH CURING DEPTH | Ivoclar Vivadent AG (LI) | 2023-02-01 | — | — | EP | claimed |
| EP-3861976-B1 | DENTAL MATERIALS BASED ON CYCLOPOLYMERISABLE CROSS-LINKING AGENTS | IVOCLAR VIVADENT AG (LI) | 2022-03-30 | — | — | EP | claimed |
| US-11278381-B2 | Monochromatic dental shaped article and blank for making dental restorations | IVOCLAR VIVADENT AG (LI) | 2022-03-22 | — | — | US | claimed |
| US-8247470-B2 | Polymerizable composition | GC CORPORATION (JP) | 2012-08-21 | — | — | US | claimed |
| EP-0951896-B1 | Radically polymerizable dental material | IVOCLAR VIVADENT AG (LI) | 2005-12-21 | — | — | EP | claimed |
| US-6833425-B1 | Filler for plastic formulations based on polyurethane | 3M ESPE AG (DE) | 2004-12-21 | — | — | US | claimed |
| EP-1222220-B1 | FILLER FOR PLASTIC FORMULATIONS BASED ON POLYURETHANE | 3M ESPE AG (DE) | 2003-08-13 | — | — | EP | claimed |
| EP-1222220-A1 | FILLER FOR PLASTIC FORMULATIONS BASED ON POLYURETHANE | 3M Espe AG (DE) | 2002-07-17 | — | — | EP | claimed |
| US-6353039-B1 | CROSSLINKING POLYMER COMPOSITES AND TRANSPARENT GLASS | IVOCLAR AG (LI) | 2002-03-05 | — | — | US | claimed |
| WO-2001018085-A1 | FILLER FOR PLASTIC FORMULATIONS BASED ON POLYURETHANE | 3M ESPE AG (DE) | 2001-03-15 | — | — | WO | claimed |
| EP-0951896-A2 | Radically polymerizable dental material | IVOCLAR AG (LI) | 1999-10-27 | — | — | EP | claimed |
| EP-0923925-A2 | Polymerisable composite material | IVOCLAR AG (LI) | 1999-06-23 | — | — | EP | claimed |
| EP-0923926-A2 | Ion leachable composite material | IVOCLAR AG (LI) | 1999-06-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793732-B2 | Dental materials based on cyclopolymerizable crosslinkers | CBR3, CBR1, C1R | TSHR 2351/4885MEN1 4379/4885KMT2A 2090/4885 |
| US-20230059534-A1 | AESTHETIC DENTAL FILLING MATERIAL HAVING HIGH CURING DEPTH | CAD, RAD51, REV1 | TSHR 4353/4885MEN1 1144/4885KMT2A 1729/4885 |
| US-12296031-B2 | Esthetic dental filling material with high depth of cure | RARA, RARG, RARB | TSHR 1956/4885MEN1 1317/4885KMT2A 1511/4885 |
| US-20230052305-A1 | Esthetic Dental Filling Material With High Depth Of Cure | RARA, RARG, RARB | TSHR 1956/4885MEN1 1317/4885KMT2A 1511/4885 |
| US-20250352435-A1 | AESTHETIC DENTAL FILLING MATERIAL HAVING HIGH CURING DEPTH | CAD, REV1, RAD51 | TSHR 4285/4885MEN1 1177/4885KMT2A 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.